[Multi-omics research contributes to early screening, diagnosis and treatment of liver cancer].

In 2016, the World Health Organization set an ambitious goal of reducing viral hepatitis-related deaths by 65% by 2030. The key to this goal is to reduce viral hepatitis-related HCC deaths. Liver cancer is the fourth most common malignant tumor and the second leading cause of cancer death in China. The onset of HCC is insidious, and most patients are already in the middle and late stage when diagnosed. Despite the great progress on management of HCC, the therapeutic effect and prognosis of HCC are still unsatisfactory. Therefore, multi-dimensional and comprehensive analysis of the mechanism of liver cancer, improving the early screening, diagnosis and treatment rate of liver cancer are the key points of reducing the harm of liver cancer in China. In recent years, multi-omics studies have been widely applied in the field of liver cancer, providing a basis for the pathogenesis of liver cancer, early detection and diagnosis, development of individual treatment strategies and prognosis assessment. This issue will focus on the application of genomics, proteomics, metabolomics and imaging omics in early screening, diagnosis and treatment of liver cancer.2016年世界卫生组织提出到2030年要将病毒性肝炎相关死亡下降65%的宏伟目标，其关键就在于降低病毒性肝炎相关肝细胞癌（HCC）的死亡率。肝癌是我国第四位高发恶性肿瘤且位居肿瘤致死病因的第二位。HCC起病隐匿，多数患者确诊时已是中晚期，尽管肝癌诊断和治疗领域取得巨大进步，但疗效和预后仍差强人意。因此，多维度全方位解析肝癌发生发展机制，提高肝癌的早筛早诊早治率是当前我国降低肝癌危害的关键环节。近年来，多组学研究被广泛应用于肝癌领域，为肝癌发生发展机制、早期发现和诊断、个体化治疗策略的制定和预后评估等方面提供了依据。本期重点号将着重就基因组学、蛋白组学、代谢组学和影像组学的多组学研究在肝癌早筛早诊早治中的应用进行深入探讨。.